Gemcitabine API (CAS No. 95058-81-4) is a synthetic pyrimidine nucleoside analogue active pharmaceutical ingredient associated with antineoplastic and oncology pharmaceutical development.
Gemcitabine, also known as 2',2'-difluorodeoxycytidine or dFdC, belongs to the class of nucleoside metabolic inhibitors and antimetabolite pharmaceutical compounds.
Gemcitabine is structurally related to deoxycytidine and contains two fluorine atoms at the 2' position of the sugar moiety. Following cellular uptake, Gemcitabine undergoes intracellular phosphorylation by nucleoside kinases to form active diphosphate and triphosphate metabolites.
Gemcitabine diphosphate, also known as dFdCDP, inhibits ribonucleotide reductase and reduces intracellular concentrations of deoxynucleotides required for DNA synthesis.
Gemcitabine triphosphate, also known as dFdCTP, competes with endogenous deoxycytidine triphosphate for incorporation into DNA. Incorporation into newly synthesized DNA interferes with DNA replication and contributes to inhibition of cell proliferation.
Gemcitabine is associated with pharmaceutical treatment strategies for several malignancies and is widely evaluated in oncology pharmaceutical development.
Pharmaceutical companies sourcing Gemcitabine API commonly evaluate assay, HPLC purity, stereochemical identity, related substances, epimeric impurities, process-related impurities, degradation products, residual solvents, water content, crystalline characteristics, and batch-to-batch consistency.
Because Gemcitabine is a stereochemically defined nucleoside analogue, control of stereochemical identity and epimer-related impurities is an important quality consideration during API qualification.
Gemcitabine free compound and Gemcitabine Hydrochloride should be treated as separate pharmaceutical material identities. Procurement, quality, formulation, and regulatory teams should confirm the exact free compound or hydrochloride salt form before commercial sourcing.
Swapnroop Drugs and Pharmaceuticals supplies Gemcitabine API for qualified pharmaceutical research, oncology drug development, analytical, formulation development, and regulated manufacturing requirements with product-specific quality documentation, pharmaceutical-grade packaging, and reliable supply-chain coordination.
Gemcitabine is a nucleoside metabolic inhibitor associated with cytotoxic antineoplastic pharmaceutical applications.
Pharmaceutical companies evaluating Gemcitabine API may review:
Product-specific API specifications should be evaluated according to the exact Gemcitabine material form, intended dosage form, target regulatory market, formulation process, and approved pharmaceutical development requirements.
Gemcitabine enters susceptible cells and undergoes phosphorylation by intracellular nucleoside kinases.
The active metabolites include Gemcitabine diphosphate and Gemcitabine triphosphate.
Gemcitabine diphosphate inhibits ribonucleotide reductase.
Ribonucleotide reductase is involved in the generation of deoxynucleotides required for DNA synthesis.
Reduction of intracellular deoxynucleotide concentrations supports increased incorporation of Gemcitabine metabolites into DNA.
Gemcitabine triphosphate competes with endogenous deoxycytidine triphosphate and becomes incorporated into newly synthesized DNA.
This process interferes with DNA synthesis and contributes to inhibition of proliferating cells.
Gemcitabine also blocks progression of cells through the G1/S-phase boundary.
Gemcitabine and Gemcitabine Hydrochloride should be treated as separate chemical material identities for website, procurement, quality, and specification purposes.
Gemcitabine free compound has CAS No. 95058-81-4, molecular formula C9H11F2N3O4, and molecular weight approximately 263.20 g/mol.
Gemcitabine Hydrochloride has CAS No. 122111-03-9, molecular formula C9H11F2N3O4·HCl, and molecular weight approximately 299.66 g/mol.
Gemcitabine Hydrochloride is the pharmaceutical salt form commonly associated with marketed injectable products.
Procurement, formulation, quality, and regulatory teams should confirm the exact free compound or hydrochloride salt form before commercial sourcing.
Gemcitabine-related pharmaceutical development is strongly associated with injectable oncology dosage forms.
Formulation and API development considerations may include:
For direct development of conventional Gemcitabine injectable pharmaceutical products, Gemcitabine Hydrochloride material specifications should be separately evaluated.
Swapnroop Drugs and Pharmaceuticals supports qualified pharmaceutical and oncology-development customers with:
Gemcitabine API is supplied in secure pharmaceutical-grade packaging selected according to product quantity, stability requirements, moisture protection requirements, and customer specifications.
Product-appropriate inner packaging and approved pharmaceutical-grade outer containers may be used according to the supplied material specification.
Available packaging configurations may include:
Packaging configuration, MOQ, commercial quantity, particle size requirements, and shipment conditions are confirmed according to the approved product specification and customer enquiry.
Store Gemcitabine API in tightly closed and appropriately labeled containers under the controlled storage conditions specified in the approved product documentation.
Protect the material from excessive moisture, heat, direct light, contamination, and unsuitable environmental exposure.
Get Bulk Quote via WhatsApp